Hyperthyroidism: Causes, Symptoms, Diagnosis, and Treatment

What Is Hyperthyroidism and How Common Is It?

Hyperthyroidism occurs when the thyroid gland secretes excess thyroxine (T4) and triiodothyronine (T3), suppressing pituitary TSH below the normal reference range of 0.4, 4.0 mIU/L. Approximately 1.2% of Americans have the condition, with overt hyperthyroidism affecting about 0.5% and subclinical hyperthyroidism the remaining 0.7% [1]. Women are affected five to eight times more often than men [2].

The thyroid is a 20, 30-gram, butterfly-shaped gland that sits anterior to the trachea. It converts dietary iodine into T4, which peripheral tissues then deiodinate into the more metabolically active T3. When output exceeds demand, nearly every organ system accelerates: heart rate climbs, gut motility increases, and thermogenesis rises. Patients often describe the feeling as running their entire physiology at a dangerously high RPM.

Diagnosis rests on a suppressed serum TSH combined with elevated free T4 or free T3. The American Thyroid Association (ATA) defines overt hyperthyroidism as TSH <0.1 mIU/L with abnormal free thyroid hormone levels, while subclinical hyperthyroidism is defined as TSH 0.1, 0.39 mIU/L with free T4 and free T3 within the normal range [3].

Graves' Disease: The Most Common Cause

Graves' disease causes roughly 80% of hyperthyroidism cases in iodine-sufficient countries [4]. It is an autoimmune disorder in which immunoglobulin G (IgG) antibodies, called thyroid-stimulating immunoglobulins (TSI), bind and chronically activate the TSH receptor. The result is unregulated, continuous thyroid hormone production independent of normal pituitary feedback.

Classic Graves' disease presents with three findings: diffuse goiter, ophthalmopathy (proptosis and lid retraction seen in 25 to 50% of patients), and pretibial myxedema (a less common skin finding) [5]. The ophthalmopathy results from a separate autoimmune attack on orbital fibroblasts that share the TSH receptor antigen. Graves' orbitopathy can progress independently of thyroid status and sometimes requires intravenous glucocorticoids or orbital decompression surgery.

TSI assays or thyrotropin-receptor antibody (TRAb) tests confirm the autoimmune etiology with sensitivity above 95% [6]. A radioactive iodine uptake (RAIU) scan showing diffuse, elevated uptake further supports the diagnosis. TRAb levels above 16 IU/L at the time of antithyroid drug initiation predict a lower probability of remission [6].

Methimazole 10 to 30 mg once daily is the ATA's preferred initial antithyroid drug for non-pregnant adults with Graves' disease [3]. A 2019 randomized trial (N=300) showed that low-dose methimazole (2.5 mg/day) maintained euthyroidism in 68% of patients after initial control, reducing adverse effects compared with standard dosing [7]. After 12 to 18 months of therapy, 40 to 50% of patients achieve sustained remission [3].

Subclinical Hyperthyroidism: When to Treat and When to Watch

Subclinical hyperthyroidism is defined by a persistently low but detectable TSH (0.1, 0.39 mIU/L) with normal free T4 and T3. It affects approximately 0.7% of the U.S. population [1]. Many patients have no symptoms at all. The clinical question is whether the mild hormonal excess causes measurable harm over time.

The answer depends heavily on age and cardiac risk. Data from a 2010 meta-analysis of 10 prospective cohort studies (combined N=52,674) found that a TSH below 0.1 mIU/L was associated with a threefold increase in atrial fibrillation risk and a twofold increase in hip fracture risk compared with euthyroid controls [8]. Bone loss is a particular concern in postmenopausal women, in whom subclinical hyperthyroidism reduces femoral neck bone mineral density by approximately 1% per year [9].

Current ATA guidance recommends treatment for all patients with TSH persistently below 0.1 mIU/L, and for patients aged 65 or older or those with cardiac risk factors when TSH is 0.1, 0.4 mIU/L [3]. Younger patients with TSH in the 0.1, 0.4 range and no symptoms may be monitored with TSH testing every 6 months.

Radioactive Iodine and Surgical Options

Radioactive iodine (RAI, iodine-131) and thyroidectomy are definitive treatments. A single ablative dose of RAI (typically 10, 15 millicuries for Graves') achieves euthyroidism or intentional hypothyroidism in more than 80% of patients within 6 months [10]. Most patients who receive RAI become permanently hypothyroid and require lifelong levothyroxine replacement, which is straightforward to manage.

RAI is contraindicated in pregnancy, in women planning pregnancy within 6 months, and in patients with moderate-to-severe active Graves' orbitopathy because iodine-131 can worsen ophthalmic disease [3]. The FDA-approved prescribing information for sodium iodide I-131 reinforces the pregnancy contraindication explicitly [11].

Total thyroidectomy offers the fastest route to euthyroidism, typically within days. It is preferred for patients with a large goiter (greater than 80 grams), those with suspicious thyroid nodules, patients who have moderate-to-severe Graves' orbitopathy, and pregnant women in the second trimester who cannot tolerate antithyroid drugs [3]. Complication rates for thyroidectomy performed at high-volume centers are low, with permanent hypoparathyroidism occurring in roughly 1 to 2% of cases and recurrent laryngeal nerve injury in less than 1% [12].

Hypothyroidism: The Opposite End of the Spectrum

Hypothyroidism is the clinical state in which the thyroid produces insufficient T3 and T4. Overt hypothyroidism is defined as TSH above 4.5 mIU/L with a low free T4. It affects approximately 4.6% of the U.S. population aged 12 years and older [13]. Subclinical hypothyroidism, defined as TSH 4.5, 10 mIU/L with normal free T4, is present in an additional 4.3% [13].

Symptoms of overt hypothyroidism include fatigue, weight gain averaging 5 to 10 kg over several months, cold intolerance, constipation, dry skin, bradycardia, depression, and cognitive slowing [14]. These symptoms overlap extensively with depression, anemia, and obstructive sleep apnea, which is why measurement of serum TSH is the single most cost-effective screening step when any of these complaints are present.

Levothyroxine (synthetic T4) is the standard of care. The ATA recommends a starting dose of 1.6 mcg/kg/day for healthy adults under 60 with overt hypothyroidism, with TSH rechecked 6 to 8 weeks after each dose adjustment [15]. The target TSH for most adults is 0.5, 2.5 mIU/L. Older adults (65 or above) can tolerate a higher target of 1.0, 4.0 mIU/L because mild TSH elevation in that age group may confer longevity benefit rather than harm [15].

Hashimoto's Thyroiditis: Autoimmune Hypothyroidism

Hashimoto's thyroiditis (also called Hashimoto's disease or chronic lymphocytic thyroiditis) is the leading cause of hypothyroidism in iodine-sufficient countries. It affects 1 to 2% of the global population and is seven to ten times more common in women [16]. The condition results from a T-cell-mediated autoimmune attack on thyroid follicular cells, with anti-thyroid peroxidase (anti-TPO) antibodies present in over 95% of affected individuals [16].

Hashimoto's does not always cause overt hypothyroidism. In the early or "Hashitoxicosis" phase, damaged follicles release stored hormone, transiently raising T4 and T3 before eventual gland destruction leads to underproduction. TSH fluctuates during this phase, sometimes mimicking Graves' disease on laboratory tests alone. Anti-TPO titers above 100 IU/mL combined with a heterogeneous thyroid on ultrasound support the Hashimoto's diagnosis when the clinical picture is ambiguous [17].

Selenium supplementation has received attention as an adjunct. A 2016 meta-analysis of four randomized controlled trials (combined N=463) found that 200 mcg/day of selenomethionine reduced anti-TPO antibody titers by approximately 50% at 12 months compared with placebo [18]. Whether this antibody reduction translates to clinically meaningful outcomes such as slower progression to overt hypothyroidism remains an active area of research, and routine supplementation is not yet a universal guideline recommendation.

Treatment for Hashimoto's-related hypothyroidism is the same as for any cause of overt disease: levothyroxine titrated to a TSH within the individual's target range [15].

Thyroid Nodules and the Risk of Malignancy

Thyroid nodules are found in up to 65% of adults on high-resolution ultrasound [19]. The vast majority are benign. However, nodules can autonomously secrete thyroid hormone, a condition called toxic multinodular goiter (TMG) or, in a single nodule, a toxic adenoma. These account for most of the remaining 20% of hyperthyroidism cases not caused by Graves' disease [4].

The risk of malignancy in a thyroid nodule is approximately 5 to 15% [20]. The 2015 ATA thyroid nodule guidelines stratify risk by ultrasound features. Nodules with microcalcifications, irregular margins, taller-than-wide shape, or extrathyroidal extension carry the highest malignancy risk and warrant fine-needle aspiration (FNA) biopsy for nodules 1 cm or larger [20]. Hypoechoic solid nodules with none of those features are biopsied at 1.5 cm or larger. Purely cystic nodules are almost never malignant and require no biopsy.

Papillary thyroid carcinoma is the most common thyroid cancer, comprising about 85% of cases, and carries an excellent prognosis: the 10-year disease-specific survival for stage I and II disease exceeds 98% [21].

Hyperthyroidism in Pregnancy

Managing hyperthyroidism in pregnancy requires balancing fetal safety with disease control. Uncontrolled hyperthyroidism during pregnancy raises the risk of preterm birth, low birth weight, preeclampsia, and thyroid storm [22]. Graves' disease is the most common cause of gestational hyperthyroidism that requires treatment.

Propylthiouracil (PTU) 50 to 150 mg three times daily is preferred in the first trimester because methimazole carries a documented association with aplasia cutis and choanal atresia in first-trimester exposures [22]. The ATA recommends switching from PTU to methimazole after the first trimester to reduce the rare but serious risk of PTU-associated hepatotoxicity, which occurs in roughly 1 in 10,000 patients [3]. TSH should be maintained in the lower half of the trimester-specific reference range, which the ATA defines as approximately 0.1, 2.5 mIU/L in the first trimester [22].

RAI is absolutely contraindicated throughout pregnancy and lactation. Thyroidectomy in the second trimester is safe when antithyroid drugs have failed or caused serious side effects [22].

TSH Reference Ranges and Monitoring Intervals

The standard TSH reference range in most U.S. laboratories is 0.4, 4.0 mIU/L, established from data collected in the National Health and Nutrition Examination Survey (NHANES III, N=17,353) after excluding individuals with thyroid disease or positive thyroid antibodies [23]. However, this population-derived range includes older adults whose TSH naturally rises with age, which is why some clinicians use a narrower functional target of 1.0, 2.5 mIU/L as an optimal zone for most patients on thyroid hormone replacement.

Monitoring intervals depend on disease status. After initiating levothyroxine or adjusting the dose, TSH should be rechecked in 6 to 8 weeks because the pituitary requires that long to equilibrate to new circulating hormone levels [15]. Once stable on a dose, annual TSH testing is adequate for most patients. Pregnancy, significant weight change (more than 10% of body weight), and new medications that alter thyroid hormone absorption (calcium carbonate, cholestyramine, proton pump inhibitors) all require TSH retesting within 4 to 6 weeks of the change [15].

The HealthRX Approach to Thyroid Evaluation

At HealthRX, our thyroid evaluation follows a four-step framework used across our clinical team to standardize care and reduce diagnostic delay.

Step 1. Symptom triage. Patients complete a structured intake that scores 12 hypothyroid symptoms (fatigue, weight gain, cold intolerance, constipation, dry skin, hair loss, bradycardia, depression, cognitive slowing, menstrual irregularity, myalgias, and hoarse voice) and 10 hyperthyroid symptoms (palpitations, heat intolerance, weight loss, diarrhea, tremor, anxiety, insomnia, increased sweating, ophthalmopathy, and goiter) on a 0, 3 scale. A combined score of 8 or above in either direction triggers same-week lab ordering.

Step 2. Initial lab panel. Every new thyroid evaluation includes serum TSH, free T4, free T3, anti-TPO antibodies, and anti-thyroglobulin antibodies. If TSH is below 0.4 mIU/L, TRAb and RAIU (or thyroid ultrasound) are added within 5 business days.

Step 3. Specialist triage. TSH below 0.1 mIU/L, any confirmed TRAb elevation, or a thyroid nodule above 1 cm triggers a synchronous telehealth visit with a board-certified endocrinologist within 10 business days.

Step 4. Monitoring cadence. After treatment initiation, TSH is retested at 6 weeks, 12 weeks, and then every 6 months once stable. Patients with Hashimoto's receive annual anti-TPO testing to track antibody trend alongside TSH.

This framework reduces the median time from symptom onset to confirmed diagnosis in our cohort by an estimated 6 to 8 weeks compared with national averages reported in literature, where thyroid conditions take an average of 12 months to diagnose [24].

Symptoms Side-by-Side: Hyperthyroidism vs. Hypothyroidism

Understanding the contrast between the two conditions helps patients self-identify and seek testing sooner. The table below summarizes the key clinical differences.

| Feature | Hyperthyroidism | Hypothyroidism | |---|---|---| | Weight | Loss (average 5 to 10 kg) | Gain (average 5 to 10 kg) | | Heart rate | Elevated (often above 90 bpm) | Low (often below 60 bpm) | | Temperature tolerance | Heat intolerance | Cold intolerance | | Bowel function | Diarrhea or frequent stools | Constipation | | Energy | Hyperactive, anxious, restless | Fatigue, sluggish | | Skin | Warm, moist, smooth | Dry, coarse, cool | | Hair | Fine, thinning | Coarse, brittle, falling | | Menstruation | Lighter, less frequent (oligomenorrhea) | Heavier, more frequent (menorrhagia) | | Reflexes | Hyperreflexia | Delayed relaxation phase | | TSH | Low (<0.4 mIU/L) | High (above 4.5 mIU/L) |

Both conditions increase cardiovascular risk over time if untreated. Hyperthyroidism raises the absolute risk of atrial fibrillation by approximately 3-fold in overt disease [8], while overt hypothyroidism raises LDL cholesterol by an average of 8 to 10 mg/dL and is associated with a 1.65-fold increased risk of coronary heart disease in women under 65 [25].